摘要:
Described herein are implantable medical devices useful in treating vascular conditions such as restenosis. In one embodiment, stents are described in which a combination of bioactive agents is described for local delivery in the vasculature. The combination of bioactive agents comprises at least one compound capable of inhibiting smooth muscle cell proliferation and at least one compound capable of mitigating MCP- and/or TF induction. For example, a compound capable of inhibiting smooth muscle cell proliferation is a mTOR inhibitor and a compound capable of mitigating MCP-1 and/or TF induction is a corticosteroid.
摘要:
Implantable medical devices having anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of certain NF-kappaB inhibitors, particularly certain dialkyl fumarates, are disclosed. Dimethyl fumarate is a particularly preferred dialkyl fumarate. The anti-restenotic medical devices include stents, catheters, micro-particles, probes and vascular grafts. Intravascular stents are preferred medical devices. The medical devices can be coated using any method known in the art including compounding the dialkyl fumarate with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-dialkyl fumarate blends are disclosed. Additionally, medical devices having a coating comprising at least one dialkyl fumarate in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the anti-restenotic implantable devices are also disclosed.
摘要:
The systems and methods of the present disclosure, in a broad aspect, provide for treatment of cardiac tissue via localized delivery of PARP inhibitors. These systems include a composition comprising at least one poly(ADP-ribose) polymerase (PARP) inhibitor; and at least one delivery device for introducing the composition into the cardiac tissue.
摘要:
Described herein are methods and medical devices used to deliver bioactive agents locally to patients in need of treatment and/or prevention of cardiovascular conditions Local delivery of protease-activated receptor 1 (PAR-1) antagonists are described herein from implantable medical devices including, but not limited to, stents.
摘要:
Methods and apparatus for aiding aneurysm repair are provided. Such apparatus is constructed to support or bolster the aneurysmal site and supply a therapeutic agent to aid in healing the surrounding aneurysmal tissue.
摘要:
Described herein are nitric oxide (NO)-donating poly(tetrafluoroethylene) (PTFE) polymers and polymer surfaces and methods of making and using the same. The NO-donating PTFE polymers can be used to fabricate at least a portion of an implantable medical device, coat at least a portion of an implantable medical device or form at least a portion of an implantable medical device. The NO-donating PTFE polymers provide controlled release of NO once implanted at or within the target site.
摘要:
A system for treating atherosclerotic cardiovascular disease and cardiac valve dysfunction comprises delivering one or more calcium chelating agents locally to a treatment site. One aspect of the invention provides a method including delivering a nano-particulate calcium chelating agent into a vascular wall. Another aspect of the invention provides a method and device for forming a sealed chamber around a cardiac valve, releasing one or more calcium chelating agents into the sealed chamber and decalcifying a cardiac valve in need thereof.
摘要:
The present disclosure relates to devices methods for the reverse transport of lipids such as cholesterols for the treatment diseases and conditions caused by vulnerable plaques. The devices can reduce or eliminate vulnerable plaques by transporting the plaques away from their location.
摘要:
Disclosed are medical devices and methods for the local delivery and treatment of vascular conditions. The methods and treatments involve local delivery of at least one matrix metalloproteinase inhibitor. The vascular conditions described herein include plaque rupture, aneurysm, stenosis, restenosis, atherosclerosis and combinations thereof.